new
emerg
human
coronaviru
report
decemb
wuhan
china
accord
world
health
organ
surveil
draft
januari
travel
wuhan
hubei
provinc
china
two
week
onset
symptom
suspect
patient
addit
distribut
interim
guidanc
laboratori
carri
test
newli
emerg
outbreak
infect
prevent
control
guidanc
viral
pneumonia
relat
seafood
market
unknown
anim
respons
emerg
outbreak
countri
start
surveil
border
prevent
spread
new
unknown
coronaviru
one
month
ago
case
confirm
posit
leav
one
dead
seven
critic
care
china
number
grossli
increas
daili
number
confirm
case
date
write
manuscript
exceed
death
januari
nation
health
commiss
china
confirm
humantohuman
transmiss
wuhan
outbreak
symptom
includ
fever
malais
dri
cough
short
breath
respiratori
distress
member
betacoronavirus
like
sever
acut
respiratori
syndrom
human
coronaviru
sar
hcov
middleeast
respiratori
syndrom
human
coronaviru
mer
hcov
today
six
differ
strain
human
coronavirus
hcov
report
addit
newli
emerg
strain
hcov
belong
alphacoronavirus
sar
mer
hcov
belong
betacoronavirus
sar
mer
hcov
aggress
strain
coronavirus
leav
death
sar
hcov
mortal
rate
mer
hcov
mortal
rate
accord
hcov
gener
positivesens
long
bp
singlestrand
rna
virus
two
group
protein
character
hcov
structur
spike
nucleocapsid
n
matrix
envelop
e
nonstructur
protein
rna
depend
rna
polymeras
rdrp
rdrp
crucial
enzym
life
cycl
rna
virus
includ
coronavirus
rdrp
target
differ
rna
virus
includ
hepat
c
viru
hcv
zika
viru
zikv
coronavirus
cov
activ
site
rdrp
highli
conserv
repres
two
success
aspart
residu
protrud
betaturn
structur
make
surfac
access
nucleotid
channel
free
nucleotid
pass
sever
vitro
clinic
trial
start
china
last
month
first
approv
drug
favilavir
nation
medic
product
administr
china
announc
yesterday
februari
zhejiang
provinc
differ
directli
act
antivir
drug
approv
virus
food
drug
administr
fda
sofosbuvir
ribavirin
rdrp
hepat
c
viru
hcv
drug
nucleotid
deriv
compet
physiolog
nucleotid
rdrp
activ
site
addit
huge
number
attempt
develop
antirdrp
compound
clinic
test
differ
virus
halfmaxim
effect
concentr
ribavirin
halfmaximum
inhibit
concentr
dengu
viru
sofosbuvir
show
zika
viru
remdesivir
show
vitro
focu
present
studi
nucleotid
inhibitor
due
strong
evid
inhibit
emerg
viral
rdrp
build
rdrp
model
use
homolog
model
sequenc
comparison
avail
structur
protein
data
bank
molecular
dock
perform
test
directact
antivir
daa
drug
rdrp
sofosbuvir
ribavirin
remidisvir
addit
nativ
nucleotid
gtp
utp
sofosbuvir
deriv
also
test
rdrp
model
result
promis
suggest
possibl
inhibit
current
avail
therapeut
newli
emerg
coronaviru
first
avail
full
genom
sequenc
newli
emerg
retriev
nation
center
biotechnolog
inform
ncbi
nucleotid
databas
swiss
model
web
server
use
build
model
rdrp
use
autom
mode
sar
hcov
solv
structur
pdb
id
chain
use
templat
share
ident
sequenc
rdrp
chain
sar
hcov
nonstructur
protein
solv
experiment
use
cryoelectron
microscopi
cryoem
resolut
deposit
protein
data
bank
last
year
molprob
web
server
duke
univers
structur
analysi
verif
server
save
univers
california
lo
angl
ucla
use
test
model
program
use
judg
valid
model
procheck
verifi
prove
errat
addit
ramachandran
plot
molprob
valid
comput
chemistri
workspac
scigress
use
minim
model
perform
molecular
dock
experi
minim
model
perform
use
forc
field
addit
miss
hydrogen
atom
dock
experi
perform
use
optim
sar
pdb
id
chain
rdrp
aid
autodock
vina
softwar
implement
scigress
eight
differ
compound
ribavirin
broadact
antivir
drug
use
treat
differ
virus
combin
immunomodul
directact
antivir
remdisivir
nucleotid
analog
use
treat
ebola
viru
marburg
viru
mer
sar
infect
cinnamaldehyd
thymoquinon
neg
control
compound
prove
inact
rdrp
hcv
zika
viru
dock
structur
examin
aid
proteinligand
interact
profil
plip
web
server
technic
univers
dresden
tabul
comparison
fig
show
multipl
sequenc
align
msa
rna
depend
rna
polymeras
differ
hcov
strain
includ
alphacoronavirus
betacoronavirus
sar
mer
sar
hcov
secondari
structur
shown
top
msa
pdb
id
chain
water
access
found
bottom
msa
highli
access
residu
blue
box
buri
residu
repres
white
bottom
msa
blackdash
rectangl
mark
activ
site
residu
success
aspart
residu
activ
site
aspart
protrud
betaturn
join
impli
msa
activ
site
highli
conserv
highlight
red
also
region
surround
highli
conserv
hcov
shown
bluedash
rectangl
region
includ
activ
site
residu
region
surround
surfac
access
though
bind
free
nucleotid
atp
gtp
ctp
utp
figur
activ
site
surfac
access
see
surfac
represent
allow
interact
free
nucleotid
pass
nucleotid
channel
rdrp
although
insert
found
rdrp
insert
apart
activ
site
aspart
littl
effect
model
qualiti
see
ramachandran
plot
addit
homolog
built
model
minim
use
forc
field
ensur
reliabl
perform
dock
studi
rdrp
percent
sequenc
ident
sar
mer
hcov
strain
respect
therefor
sar
hcov
rdrp
closest
strain
complet
genom
wuhan
sarslik
hcov
sequenc
ident
bat
sarslik
coronaviru
isol
sar
coronaviru
zsc
respect
inform
import
drug
design
find
quick
potent
solut
newli
emerg
strain
rdrp
model
residu
built
aid
autom
homolog
model
swiss
model
web
server
use
sar
hcov
rdrp
pdb
id
chain
homolog
model
high
sequenc
ident
templat
suggest
highqual
model
could
obtain
model
valid
base
valu
obtain
valid
web
server
ramachandran
plot
show
residu
allow
region
favor
region
fig
addit
residu
averag
score
base
verifi
softwar
overal
qualiti
factor
errat
perform
dock
studi
structur
small
molecul
gtp
utp
sofosbuvir
ribavirin
remdisivir
cinnamaldehyd
thymoquinon
prepar
ensur
optim
triphosph
form
optim
perform
use
forc
field
optim
accomplish
function
densiti
function
theori
dft
quantum
mechan
activ
site
aspart
treat
flexibl
dock
experi
grid
box
size
center
x
z
use
dock
util
autodock
tool
autodock
vina
util
score
function
vina
predict
interact
abovement
ligand
rdrp
activ
site
fig
show
dock
score
valu
blue
column
sar
hcov
orang
column
sar
solv
structur
pdb
id
chain
use
dock
ligand
order
compar
bind
energi
rdrp
grid
box
sar
rdrp
center
reflect
dock
score
eight
compound
includ
physiolog
gtp
utp
four
drug
sofosbuvir
ribavirin
remidisvir
bind
sar
hcov
rdrp
good
bind
energi
kcalmol
despit
sar
hcov
rdrp
show
slightli
higher
bind
energi
lower
bind
compar
rdrp
differ
still
nonsignific
ribavirin
remdisivir
sofosbuvir
parent
nucleotid
utp
averag
kcalmol
differ
sar
rdrp
bind
energi
compound
hand
differ
sar
hcov
rdrp
bind
energi
parent
nucleotid
gtp
kcalmol
respect
addit
test
compound
show
lower
better
bind
energi
rdrp
compar
sar
rdrp
neg
control
compound
cinnamaldehyd
thymoquinon
show
lower
bind
affin
either
sar
higher
kcalmol
order
check
possibl
reason
differ
bind
energi
examin
interact
complex
form
dock
aid
plip
web
server
fig
show
form
interact
daa
drug
rdrp
dock
dock
score
list
complex
reflect
bind
potenc
ligand
shown
orang
stick
protein
residu
cyan
stick
represent
label
onelett
code
hbond
solid
blue
line
dash
line
repres
hydrophob
interact
one
salt
bridg
yellow
sphere
connect
dash
line
form
case
respons
increas
stabil
form
complex
reflect
dock
score
number
hbond
sofosbuvir
ribavirin
respect
hand
sofosbuvir
form
metal
interact
mg
two
interact
respect
anoth
reason
increas
stabil
form
complex
sofosbuvir
addit
sofosbuvir
form
two
hydrophob
interact
rdrp
summar
abovement
data
say
sofosbuvir
ribavirin
tightli
bind
newli
emerg
coronaviru
rdrp
henc
contradict
function
protein
lead
viral
erad
addit
show
promis
result
come
sofosbuvir
potent
inhibitor
newli
emerg
strain
hcov
optim
two
compound
result
potent
compound
abl
stop
newli
emerg
infect
newli
emerg
coronaviru
wuhan
citi
china
health
concern
sinc
last
outbreak
type
virus
sar
year
countri
leav
death
case
hospit
besid
anoth
outbreak
middl
east
region
entir
differ
infect
pattern
mer
leav
death
hospit
present
studi
aim
test
suggest
possibl
inhibitor
daa
drug
current
market
stop
infect
immedi
sofosbuvir
ribavirin
remdisivir
use
new
strain
coronaviru
emerg
promis
result
gtp
deriv
may
use
specif
inhibitor
dock
structur
avail
upon
request
correspond
author
author
declar
compet
interest
work
